Equities analysts expect that Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) will post ($0.86) earnings per share for the current quarter, Zacks reports. Three analysts have made estimates for Repare Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.80) and the lowest estimate coming in at ($0.91). Repare Therapeutics reported earnings per share of ($0.71) in the same quarter last year, which suggests a negative year-over-year growth rate of 21.1%. The business is expected to issue its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Repare Therapeutics will report full year earnings of ($3.37) per share for the current fiscal year, with EPS estimates ranging from ($3.64) to ($2.92). For the next year, analysts anticipate that the company will report earnings of ($3.82) per share, with EPS estimates ranging from ($4.09) to ($3.17). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Repare Therapeutics.
Repare Therapeutics (NASDAQ:RPTX – Get Rating) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.03. Repare Therapeutics had a negative net margin of 1,533.38% and a negative return on equity of 47.60%.
Shares of Repare Therapeutics stock opened at $12.09 on Friday. The firm’s 50 day moving average price is $11.10 and its 200-day moving average price is $15.44. Repare Therapeutics has a 52-week low of $8.06 and a 52-week high of $35.75. The company has a market cap of $506.45 million, a P/E ratio of -4.13 and a beta of 0.92.
In related news, major shareholder Bvf Partners L. P/Il purchased 420,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 18th. The stock was bought at an average price of $8.50 per share, with a total value of $3,570,000.00. Following the acquisition, the insider now owns 3,350,950 shares in the company, valued at $28,483,075. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 33.60% of the stock is currently owned by insiders.
Several institutional investors have recently added to or reduced their stakes in RPTX. National Bank of Canada FI purchased a new stake in shares of Repare Therapeutics during the fourth quarter worth $43,000. Legal & General Group Plc grew its holdings in shares of Repare Therapeutics by 55.5% in the fourth quarter. Legal & General Group Plc now owns 3,923 shares of the company’s stock valued at $83,000 after purchasing an additional 1,400 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in Repare Therapeutics by 9.5% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,580 shares of the company’s stock valued at $165,000 after buying an additional 1,002 shares during the last quarter. Virtus ETF Advisers LLC lifted its position in Repare Therapeutics by 28.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 8,355 shares of the company’s stock valued at $176,000 after buying an additional 1,873 shares during the last quarter. Finally, California State Teachers Retirement System acquired a new position in Repare Therapeutics in the third quarter valued at about $198,000. 89.66% of the stock is owned by institutional investors and hedge funds.
Repare Therapeutics Company Profile (Get Rating)
Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.
- Get a free copy of the StockNews.com research report on Repare Therapeutics (RPTX)
- Dividend Capture Strategy: What You Need to Know
- Okta On Verge Of Multi-Week Rally
- Don’t Bet On A Bounce For RH
- Xiaomi Co: Facing Macro Headwinds
- Alibaba Group: Rallying on Fundamentals & Improved Macro Backdrop
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.